Ahmedabad, India | February 26, 2025 – Zydus Lifesciences Limited (BSE: 532321, NSE: Zyduslife) has announced the launch of
VaxiFlu-4, a
Quadrivalent Inactivated Influenza vaccine, making it the first Indian pharmaceutical company to introduce protection against the
2025 Southern Hemisphere influenza strains.
Key Highlights of VaxiFlu-4:
- Developed in line with the WHO's recommended composition for 2025.
- Protects against four new strains:
- A/Victoria/4897/2022 (H1N1)pdm09-like virus
- A/Croatia/10136RV/2023 (H3N2)-like virus
- B/Austria/1359417/2021 (B/Victoria lineage)-like virus
- B/Phuket/3073/2013 (B/Yamagata lineage)-like virus
- Approved by Central Drug Laboratory (CDL).
- Marketed by Zydus Vaxxicare, a division dedicated to preventive healthcare.
A Step Towards Stronger Flu Protection
The new quadrivalent vaccine ensures broader coverage by protecting against both
influenza A and B strains, reducing the risk of vaccine mismatch and seasonal flu outbreaks. The vaccine has been developed at Zydus'
Vaccine Technology Centre (VTC) in Ahmedabad, which specializes in
innovative and effective vaccines.
Management Commentary
Dr. Sharvil Patel, Managing Director, Zydus Lifesciences, emphasized the critical role of vaccines in preventing seasonal outbreaks:
“Preventives are key to public health in both the developing and developed world. In India, access to affordable, high-quality vaccines remains a priority. With VaxiFlu-4, we aim to strengthen annual immunization efforts and prevent flu-related complications.”
Addressing Public Health Concerns
The
World Health Organization (WHO) estimates that seasonal influenza leads to
290,000–650,000 deaths globally each year. Influenza spreads through
airborne respiratory droplets or direct contact, causing severe illness, particularly in
children under five, the elderly, and immunocompromised individuals.
Zydus' Commitment to Vaccine Development
Zydus Lifesciences has developed
17 vaccines, including those for
Typhoid, Hepatitis B, and Rabies. Several others, including
Hepatitis A, Hepatitis E, MMRV, and Bivalent Typhoid-Paratyphoid A vaccines, are currently in
clinical trials.
Conclusion
With the launch of
VaxiFlu-4, Zydus Lifesciences reinforces its commitment to
public health innovation and
global flu prevention efforts. This milestone positions the company as a
leader in India's vaccine landscape, supporting widespread immunization and disease prevention.